Head-to-head evidence
albuterol sulfate (Amphastar) vs Salmeterol (DISKUS)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol sulfate (Amphastar)
Developed by Amphastar Pharmaceuticals, Inc.
NCT01581177 · Phase 2 · completed
The study randomized 23 participants and used triple blinding with placebo and active albuterol comparators, but its small sample and unreported results limit the strength of the evidence. The primary outcome was change in FEV1 AUC, a physiological surrogate measure, and the registry does not state whether this comparison was successful.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
Salmeterol (DISKUS)
Marketed by GlaxoSmithKline
NCT00395304 · Phase 3 · completed
This was a rigorously designed, fully blinded, randomized crossover trial with a clinically meaningful composite primary measure, but the results available here do not show how the fluticasone-plus-salmeterol arm specifically compared with the other step-up therapies, so the salmeterol-specific effect cannot be confirmed from this data.
Next expected readout: June 2027 · NCT06676319 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol sulfate (Amphastar)'s landscape · Salmeterol (DISKUS)'s landscape